Natera (NASDAQ:NTRA) Price Target Raised to $250.00 at Canaccord Genuity Group

by · The Cerbat Gem

Natera (NASDAQ:NTRA – Get Free Report) had its price target raised by research analysts at Canaccord Genuity Group from $200.00 to $250.00 in a research note issued to investors on Friday,Benzinga reports. The firm presently has a “buy” rating on the medical research company’s stock. Canaccord Genuity Group’s price target would indicate a potential upside of 25.27% from the company’s current price.

Other equities analysts have also issued research reports about the stock. BNP Paribas Exane upgraded shares of Natera from an “underperform” rating to a “neutral” rating and set a $172.00 target price on the stock in a report on Monday, October 27th. Weiss Ratings reissued a “sell (d-)” rating on shares of Natera in a research note on Wednesday, October 8th. Morgan Stanley restated an “overweight” rating and set a $195.00 price objective on shares of Natera in a report on Sunday, August 10th. Barclays lifted their price objective on shares of Natera from $210.00 to $230.00 and gave the company an “overweight” rating in a report on Friday. Finally, Piper Sandler reissued an “overweight” rating and issued a $220.00 price objective (up from $210.00) on shares of Natera in a research note on Monday, August 11th. Seventeen investment analysts have rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $206.74.

Read Our Latest Stock Report on NTRA

Natera Stock Performance

Shares of Natera stock traded up $1.09 on Friday, hitting $199.57. The stock had a trading volume of 2,706,980 shares, compared to its average volume of 1,426,347. The stock has a 50 day moving average of $177.12 and a 200 day moving average of $163.28. Natera has a twelve month low of $125.38 and a twelve month high of $203.23. The firm has a market capitalization of $27.39 billion, a P/E ratio of -104.49 and a beta of 1.75.

Natera (NASDAQ:NTRA – Get Free Report) last issued its quarterly earnings results on Thursday, November 6th. The medical research company reported ($0.64) earnings per share for the quarter, missing the consensus estimate of ($0.39) by ($0.25). The company had revenue of $592.18 million during the quarter, compared to analyst estimates of $514.55 million. Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The company’s quarterly revenue was up 34.7% on a year-over-year basis. During the same period in the previous year, the company posted ($0.26) EPS. Natera has set its FY 2025 guidance at EPS. Equities analysts expect that Natera will post -1.49 earnings per share for the current year.

Insider Activity at Natera

In other Natera news, CEO Steven Leonard Chapman sold 160,703 shares of Natera stock in a transaction that occurred on Monday, November 3rd. The shares were sold at an average price of $199.96, for a total transaction of $32,134,171.88. Following the completion of the sale, the chief executive officer directly owned 144,816 shares in the company, valued at approximately $28,957,407.36. The trade was a 52.60% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, insider John Fesko sold 928 shares of the company’s stock in a transaction on Tuesday, October 28th. The shares were sold at an average price of $191.46, for a total transaction of $177,674.88. Following the completion of the sale, the insider directly owned 150,699 shares in the company, valued at approximately $28,852,830.54. The trade was a 0.61% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 224,889 shares of company stock worth $43,232,062 in the last quarter. 5.63% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Natera

A number of large investors have recently added to or reduced their stakes in the stock. Bank of Jackson Hole Trust purchased a new stake in shares of Natera during the first quarter worth $29,000. TCTC Holdings LLC increased its stake in Natera by 114.8% during the first quarter. TCTC Holdings LLC now owns 232 shares of the medical research company’s stock worth $33,000 after purchasing an additional 124 shares during the period. Northwestern Mutual Wealth Management Co. increased its holdings in Natera by 83.5% during the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company’s stock worth $33,000 after purchasing an additional 106 shares during the period. Hilltop National Bank acquired a new stake in shares of Natera in the 2nd quarter valued at $33,000. Finally, Oliver Lagore Vanvalin Investment Group purchased a new stake in Natera during the second quarter worth approximately $36,000. 99.90% of the stock is currently owned by institutional investors and hedge funds.

About Natera

(Get Free Report)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Featured Articles